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Abstract
In Randomised Controlled Trials (RCT) with treatment non-compliance, instrumental variable
approaches are used to estimate complier average causal effects. We extend these approaches to
cost-effectiveness analyses, where methods need to recognise the correlation between cost and health
outcomes.
We propose a Bayesian full likelihood (BFL) approach, which jointly models the effects of
random assignment on treatment received and the outcomes, and a three-stage least squares (3sls)
method, which acknowledges the correlation between the endpoints, and the endogeneity of the
treatment received.
This investigation is motivated by the REFLUX study, which exemplifies the setting where
compliance differs between the RCT and routine practice. A simulation is used to compare the
methods performance.
We find that failure to model the correlation between the outcomes and treatment received
correctly can result in poor CI coverage and biased estimates. By contrast, BFL and 3sls methods
provide unbiased estimates with good coverage.
Keywords: non-compliance, instrumental variables, bivariate outcomes, cost-effectiveness
1 Introduction
Non-compliance is a common problem in Randomised Controlled Trials (RCTs), as some participants
depart from their randomised treatment, by for example switching from the experimental to the con-
trol regimen. An unbiased estimate of the effectiveness of treatment assignment can be obtained by
reporting the intention-to-treat (ITT) estimand. In the presence of non-compliance, a complimentary
estimand of interest is the causal effect of treatment received. Instrumental variable (IV) methods can
be used to obtain the complier average causal effect (CACE), as long as random assignment meets
the IV criteria for identification (Angrist et al., 1996). An established approach to IV estimation is
two-stage least squares (2sls), which provides consistent estimates of the CACE when the outcome
measure is continuous, and non-compliance is binary (Baiocchi et al., 2014).
Cost-effectiveness analyses (CEA) are an important source of evidence for informing clinical decision-
making and health policy. CEA commonly report an ITT estimand, i.e. the relative cost-effectiveness
of the intention to receive the intervention (NICE, 2013). However, policy-makers may require ad-
ditional estimands, such as the relative cost-effectiveness for compliers. For example, CEAs of new
therapies for end-stage cancer, are required to estimate the cost-effectiveness of treatment receipt,
recognising that patients may switch from their randomised allocation following disease progression.
Alternative estimates such as the CACE may also be useful when levels of compliance in the RCT differ
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to those in the target population, or where intervention receipt, rather than the intention to receive
the intervention, is the principal cost driver. Methods for obtaining the CACE for univariate survival
outcomes have been exemplified before (Latimer et al., 2014), but approaches for obtaining estimates
that adequately adjust for non-adherence in CEA more generally, have received little attention. This
has been recently identified as a key area where methodological development is needed (Hughes et al.,
2016).
The context of trial-based CEA highlights an important complexity that arises with multivariate
outcomes more widely, in that, to provide accurate measures of the uncertainty surrounding a composite
measure of interest, for example the incremental net monetary benefit (INB), it is necessary to recognise
the correlation between the endpoints, in this case, cost and health outcomes (Willan et al., 2003;
Willan, 2006). Indeed, when faced with non-compliance, and the requirement to estimate a causal
effect of treatment on cost-effectiveness endpoints, some CEA resort to per protocol (PP) analyses
(Brilleman et al., 2015), which exclude participants who deviate from treatment. As non-compliance
is likely to be associated with prognostic variables, only some of which are observed, PP analyses are
liable to provide biased estimates of the causal effect of the treatment received.
This paper develops novel methods for estimating CACE in CEA that use data from RCTs with
non-compliance. First, we propose using the three stage least squares (3sls) method (Zellner and Theil,
1962), which allows the estimation of a system of simultaneous equations with endogenous regressors.
Next, we consider a bivariate version of the ‘unadjusted Bayesian’ models previously proposed for
Mendelian randomisation (Burgess and Thompson, 2012), which simultaneously estimate the expected
treatment received as a function of random allocation, and the mean outcomes as a linear function
of the expected treatment received. Finally, we develop a Bayesian full likelihood approach (BFL),
whereby the outcome variables and the treatment received are jointly modelled as dependent on the
random assignment. This is an extension to the multivariate case of what is known in the econometrics
literature as the IV unrestricted reduced form (Kleibergen and Zivot, 2003).
The aim of this paper is to present and compare these alternative approaches. The problem
is illustrated in Section 2 with the REFLUX study, a multicentre RCT and CEA that contrasts
laparoscopic surgery with medical management for patients with Gastro-Oesophageal Reflux Disease
(GORD). Section 3 introduces the assumptions and methods for estimating CACEs. Section 4 presents
a simulation study used to assess the performance of the alternative approaches, which are then applied
to the case study in Section 5. We conclude with a Discussion (Section 6), where we consider the
findings from this study in the context of related research.
2 Motivating example: Cost-effectiveness analysis of the REFLUX
study
The REFLUX study was a UK multicentre RCT with a parallel design, in which patients with moder-
ately severe GORD, were randomly assigned to medical management or laparoscopic surgery (Grant
et al., 2008, 2013).
The RCT randomised 357 participants (178 surgical, 179 medical) from 21 UK centres. An obser-
vational preference based study was conducted alongside it, which involved 453 preference participants
(261 surgical, 192 medical).
For the cost-effectiveness analysis within the trial, individual resource use (costs in £ sterling) and
health-related quality of life (HRQoL), measured using EQ5D (3 levels), were recorded annually for
up to 5 years. The HRQoL data were used to adjust life years and present quality-adjusted life years
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(QALYs) over the follow-up period (Grant et al., 2013).1 As is typical, the costs were right-skewed.
Table 1 reports the main characteristics of the data set.
The original CEA estimated the linear additive treatment effect on mean costs and health outcomes
(QALYs). The primary analysis used a system of seemingly unrelated regression equations (SURs)
(Zellner, 1962; Willan et al., 2004), adjusting for baseline HRQoL EQ5D summary score (denoted by
EQ5D0). The SURs can be written for cost Y1i and QALYs Y2i, as follows
Y1i = β0,1 + β1,1treati + β1,2EQ5D0i + 1i
Y2i = β0,2 + β1,2treati + β2,2EQ5D0i + 2i
(1)
where β1,1 and β1,2 represent the incremental costs and QALYs respectively. The error terms are
required to satisfy E[1i] = E[2i] = 0, E[kik′i] = σkk′ , E[kik′j ] = 0, for k, k′ ∈ {1, 2}, and for i 6=
j. Rather than assuming that the errors are drawn from a bivariate normal distribution, estimation
is usually done by the feasible generalized least squares (FGLS) method2. This is a two-step method
where, in the first step, we run ordinary least squares estimation for equation (1). In the second step,
residuals from the first step are used as estimates of the elements σkk′ of the covariance matrix, and
this estimated covariance structure is then used to re-estimate the coefficients in equation (1) (Zellner,
1962; Zellner and Huang, 1962).
In addition to reporting incremental costs and QALYs, CEA often report the incremental cost-
effectiveness ratio (ICER), which is defined as the ratio of the incremental costs per incremental
QALY, and the incremental net benefit (INB), defined as INB(λ) = λβ1,2 − β1,1, where λ represents
the decision-makers’ willingness to pay for a one unit gain in health outcome. Thus the new treatment
is cost-effective if INB > 0. For a given λ, the standard error of INB can be estimated from the
estimated increments βˆ1,1 and βˆ1,2, together with their standard errors and their correlation following
the usual rules for the variance of a linear combination of two random variables. The willingness to pay
λ generally lies in a range, so it is common to compute the estimated value of INB for various values
of λ. In REFLUX, the reported INB was calculated using λ = £30000, which is within the range of
cost-effectiveness thresholds used by the UK National Institute for Health and Care Excellence (NICE,
2013).
The original ITT analysis concluded that, compared to medical management, the arm assigned to
surgery had a large gain in average QALYs, at a small additional cost and was relatively cost-effective
with a positive mean INB, albeit with 95% confidence intervals (CI) that included zero. However,
these ITT results cannot be interpreted as a causal effect of the treatment, since within one year of
randomisation, 47 of those randomised to surgery switched and received medical management, while
in the medical treatment arm, 10 received surgery. The reported reasons for not having the allocated
surgery were that in the opinion of the surgeon or the patient, the symptons were not “sufficiently severe”
or the patient was judged unfit for surgery (e.g. overweight). The preference-based observational study
conducted alongside the RCT reported that in routine clinical practice, the corresponding proportion
who switched from an intention to have surgery and received medical management, was relatively
low (4%), with a further 2% switching from control to intervention (Grant et al., 2013). Since the
percentage of patients who switched in the RCT was higher than in the target population and the
costs of the receipt of surgery are relatively large, there was interest in reporting a causal estimate of
the intervention. Thus, the original study also reported a PP analysis on complete-cases, adjusted for
baseline EQ5D0, which resulted in an ICER of £7263 per additional QALY (Grant et al., 2013). This
is not an unbiased estimate of the causal treatment effect, so in Section 5, we re-analyse the REFLUX
1There was no administrative censoring.
2If we are prepared to assume the errors are bivariate normal, estimation can proceed by maximum likelihood.
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dataset to obtain a CACE of the cost-effectiveness outcomes, recognising the joint distribution of costs
and QALYs, using the methods described in the next section.
3 Complier Average Causal effects with bivariate outcomes
We begin by defining more formally our estimands and assumptions. Let Y1i and Y2i be the continuous
bivariate outcomes, and Zi and Di the binary random treatment allocation and treatment received
respectively, corresponding to the i-th individual. The bivariate endpoints Y1i and Y2i belong to the
same individual i, and thus are correlated. We assume that there is an unobserved confounder U ,
which is associated with the treatment received and either or both of the outcomes. From now on,
we will assume that the (i) Stable Unit Treatment Value Assumption (SUTVA) holds: the
potential outcomes of the i-th individual are unrelated to the treatment status of all other individuals
(known as no interference), and that for those who actually received treatment level z, their observed
outcome is the potential outcome corresponding to that level of treatment.
Under SUTVA, we can write the potential treatment received by the i-th subject under the random
assignment at level zi ∈ {0, 1} asDi (zi). Similarly, Y`i (zi, di) with ` ∈ {1, 2} denotes the corresponding
potential outcome for endpoint `, if the i-th subject were allocated to level zi of the treatment and
received level di. There are four potential outcomes. Since each subject is randomised to one level of
treatment, only one of the potential outcomes per endpoint `, is observed, i.e. Y`i = Y`i(zi, Di(zi)) =
Yi(zi).
The CACE for outcome ` can now be defined as
θ` = E
[{Y`i(1)− Y`i(0)}∣∣{Di(1)−Di(0) = 1}] . (2)
In addition to (i) SUTVA, the following assumptions are sufficient for identification of the CACE,
(Angrist et al., 1996):
(ii) Ignorability of the treatment assignment: Zi is independent of unmeasured confounders
(conditional on measured covariates) and the potential outcomes Zi ⊥⊥ Ui, Di(0), Di(1), Yi(0), Yi(1).
(iii) The random assignment predicts treatment received: Pr{Di(1) = 1} 6= Pr{Di(0) = 1}.
(iv) Exclusion restriction: The effect of Z on Y` must be via an effect of Z on D; Z cannot affect
Y` directly.
(v) Monotonicity: Di(1) ≥ Di(0).
The CACE can now be identified from equation (2) without any further assumptions about the
unobserved confounder; in fact, U can be an effect modifier of the relationship of D and Y (Didilez
et al., 2010).
In the REFLUX study, the assumptions concerning the random assignment, (ii) and (iii), are
justified by design. The exclusion restriction assumption seems plausible for the costs, since the costs
of surgery are only incurred if the patient actually has the procedure. We argue that it is also plausible
that it holds for QALYs, as the participants did not seem to have a preference for either treatment,
thus making the psychological effects of knowing to which treatment one has been allocated minimal.
The monotonicity assumption rules out the presence of defiers. It seems fair to assume that there
are no participants who would refuse the REFLUX surgery when randomised to it, but who would
receive surgery when randomised to receive medical management. Equation (2) implicitly assumes
that receiving the intervention has the same average effect in the linear scale, regardless of the level of
Z and U . This average is however across different ‘versions’ of the intervention, as the trial protocol
did not prescribe a single surgical procedure, but allowed for the surgeon to choose their preferred
laparoscopy method, as would be the case in routine clinical practice.
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Since random allocation, Z, satisfies assumptions (ii)-(iv), we say it is an instrument (or instru-
mental variable) for D. For binary instrument, the simplest method of estimation of equation (2) in
the IV framework is the Wald estimator (Angrist et al., 1996):
θˆ`,IV =
E(Y |Z = 1)− E(Y |Z = 0)
E(D|Z = 1)− E(D|Z = 0)
Typically, estimation of these conditional expectations proceeds via an approach known as two-stage
least squares (2sls). The first stage fits a linear regression to treatment received on treatment assigned.
Then, in a second stage, a regression model for the outcome on the predicted treatment received is
fitted:
Di = α0 + α1Zi + ω1i
Y`i = β0 + βIV Dˆi + ω2i (3)
where βˆIV is an estimator for θ`. Covariates can be used, by including them in both stages of the
model. To obtain the correct standard errors for the 2sls estimator, it is necessary to take into account
the uncertainty about the first stage estimates. The asymptotic standard error for the 2sls CACE is
given in Imbens and Angrist (1994), and implemented in commonly used software packages.
OLS estimation produces first-stage residuals ω1i that are uncorrelated with the instrument, and
this is sufficient to guarantee that the 2sls estimator is consistent for the CACE (Angrist et al., 2008).
Therefore, we restrict our attention here to models where the first-stage equation is linear, even though
the treatment received is binary. 3
A key issue for settings such as CEA where there is interest in estimating the CACE for bivari-
ate outcomes, is that 2sls as implemented in most software packages can only be readily applied to
univariate outcomes. Ignoring the correlation between the two endpoints is a concern for obtaining
standard errors of composite measures of the outcomes, e.g. INB, as this requires accurate estimates
of the covariance between the outcomes of interest (e.g. costs and QALYs).
A simple way to address this problem would be to apply 2sls directly to the composite measure,
i.e. a net-benefit two-stage regression approach (Hoch et al., 2006). However, it is known that net
benefit regression is very sensitive to outliers, and to distributional assumptions (Willan et al., 2004),
and has been recently shown to perform poorly when these assumptions are thought to be violated
(Mantopoulos et al., 2016). Moreover, such net benefit regression is restrictive, in that it does not
allow separate covariate adjustment for each of the component outcomes, (e.g. baseline HRQoL, for
the QALYs as opposed to the costs). In addition, this simple approach would not be valid for estimating
the ICER, which is a non-linear function of the incremental costs and QALYs. For these reasons, we
do not consider this approach further. Rather, we present here three flexible strategies for estimating
a CACE of the QALYs and the costs, jointly. The first approach combines SURs (equation 1) and
2sls (equation 3) to obtain CACEs for both outcomes accounting for their correlation. This simple
approach is known in the econometrics literature as three-stage least squares (3sls).
3.1 Three-stage least squares
Three-stage least squares (3sls) was developed for SUR systems with endogenous regressors, i.e. any
explanatory variables which are correlated with the error term in equations (1) (Zellner and Theil,
1962). All the parameters appearing in the system are estimated jointly, in three stages. The first two
3Non-linear versions of the 2sls exist. See for example Clarke and Windmeijer (2012) for an excellent review of
methods for binary outcomes.
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stages are as for 2sls, but with the second stage applied to each of the outcomes.
(1st stage): Di = α0 + α1Zi + e0i
(2nd stage): Y1i = β01 + βIV,1Dˆi + e1i (4)
Y2i = β02 + βIV,2Dˆi + e2i (5)
As with 2sls, the models can be extended to include baseline covariates. The third stage is the same
step used on a SUR with exogenous regressors (equation (1)) for estimating the covariance matrix of
the error terms from the two equations (4) and (5). Thus, because we are assuming that Z satisfies
the identification assumptions (i)-(v), Z is independent of the residuals at first and second stage, i.e.
Z ⊥⊥ e0i, Z ⊥⊥ e1i, and Z ⊥⊥ e2i. Then, the 3sls procedure allows us to obtain the covariance matrix
between the residuals e1i and e2i. As with SURs, the 3sls approach does not require to make any
distributional assumptions, as estimation can be done by FGLS, and it is robust to heteroscedasticity
of the errors in the linear models for the outcomes (Greene, 2002). We note that the 3sls estimator
based on FGLS is consistent only if the error terms in each equation of the system and the instrument
are independent, which is likely to hold here, as we are dealing with a randomised instrument. In
settings where this condition is not satisfied, other estimation approaches such as generalised methods
of moments (GMM) warrant consideration (Schmidt, 1990). In the just-identified case, i.e. when there
are as many endogenous regressors as there are instruments, classical theory about 3sls estimators
shows that the GMM and the FGLS estimators coincide (Greene, 2002). As the 3sls method uses an
estimated variance-covariance matrix, it is only asymptotically efficient (Greene, 2002).
3.2 Naive Bayesian estimators
Bayesian models have a natural appeal for cost-effectiveness analyses, as they afford us the flexibility
to estimate bivariate models on the expectations of the two outcomes using different distributions, as
proposed by (Nixon and Thompson, 2005). These models are often specified by writing a marginal
model for one of the outcomes, e.g. the costs Y1, and then, a model for Y2, conditional on Y1.
For simplicity of exposition, we begin by assuming normality for both outcomes and no adjustment
for covariates. We have a marginal model for Y1 and a model for Y2 conditional on Y1 (Nixon and
Thompson, 2005)
Y1i ∼ N(µ1i, σ21) µ1i = β0,1 + β1,1treati (6)
Y2i | Y1i ∼ N(µ2i, σ22(1− ρ2)) µ2i = β0,2 + β1,2treati + β2,2(y1i − µ1i), (7)
where ρ is the correlation between the outcomes. The linear relationship between the two outcomes is
represented by β2,2 = ρσ2σ1 .
Because of the non-compliance, in order to obtain a causal estimate of treatment, we need to add a
linear model for the treatment received, dependent on randomisation Zi, similar to the first equation
of a 2sls. Formally, this model (denoted uBN, for unadjusted Bayesian Normal) can be written with
three equations as follows:
Di ∼ N(µ0i, σ20)
Y1i ∼ N(µ1i, σ21)
Y2i
∣∣Y1i ∼ N(µ2i, σ22(1− ρ2))
µ0i = β0,0 + β1,0Zi
µ1i = β0,1 + β1,1µ0i
µ2i = β0,2 + β1,2µ0i + β2,2(y1i − µ1i)
(8)
This model is a bivariate version of the ‘unadjusted Bayesian’ method previously proposed for Mendelian
randomisation (Burgess and Thompson, 2012). It is called unadjusted, because the variance structure
of the outcomes is assumed to be independent of the treatment received. The causal treatment effect
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for outcome Y`, with ` ∈ {1, 2}, is represented by β1,` in equations (8). We use the Fisher’s z-transform
of ρ, i.e. z = 12 log
(
1+ρ
1−ρ
)
, for which we assume a vague normal prior, i.e. z ∼ N(0, 102). We also use
vague multivariate normal priors for the regression coefficient (with a precision of 0.01). For standard
deviations, we use σj ∼ Unif(0, 10), for j ∈ {0, 1, 2}. This is similar to the priors used in (Lancaster,
2004), and are independent of the regression coefficient of treatment received on treatment allocation
β1,0.
Cost data are notoriously right-skewed, and Gamma-distributions are often used to model them.
Thus, we can relax the normality assumption of equation (8), and model Y1 (i.e. cost) with a Gamma
distribution, and treatment received (binary), with a logistic regression. The health outcomes, Y2, are
still modelled with a normal distribution, as is customary. Because we are using a non-linear model for
the treatment received, we use the predicted raw residuals from this model as extra regressors in the
outcome models, similar to the 2-stage residual inclusion estimator (Terza et al., 2008). We model Y1
by its marginal distribution (Gamma) and Y2 by a conditional Normal distribution, given Y1 (Nixon
and Thompson, 2005). We call this model ‘unadjusted Bayesian Gamma-Normal’ (uBGN) and write
it as follows
Di ∼ Bern(pii)
Y1i ∼ Gamma(ν1i, κ1)
Y2i | Y1i ∼ N(µ2i, σ22(1− ρ2))
logit(pii) = α0 + α1Zi
ri = Di − pii
µ1i = β0,1 + β1,1Di + β1,rri
µ2i = β0,2 + β1,2Di + β2,rri + β2,2(y1i − µ1i)
(9)
where µ1 = ν1κ1 , is the mean of the Gamma distributed costs, with shape ν1 and rate κ1. Again,
we express β2,2 = ρσ2σ1 , and assume a vague Normal prior on the Fisher’s z-transform of ρ, z ∼
N(0, 102).The prior distribution for ν1 is Gamma(0.01, 0.01). We also assume a Gamma prior for the
intercept term of the cost equation, β0,1 ∼ Gamma(0.01, 0.01). All the other regression parameters
have the same priors as those used in the uBN model.
The models introduced in this section, uBN and uBGN, are estimated in one stage, allowing feed-
back between the regression equations and the propagation of uncertainty. However, these ’unadjusted’
methods ignore the correlation between the outcomes and the treatment received. This misspecifica-
tion of the covariance structure may result in biases in the causal effect, which are likely to be more
important at higher levels of non-compliance.
3.3 Bayesian simultaneous equations (BFL)
We now introduce an approach that models the covariance between treatment received and outcomes
appropriately, using a system of simultaneous equations. This can be done via full or limited informa-
tion maximum likelihood, or by using MCMC to estimate the parameters in the model simultaneously
allowing for proper Bayesian feedback and propagation of uncertainty. Here, we propose a Bayesian
approach which is an extension of the methods presented in Burgess and Thompson (2012); Kleibergen
and Zivot (2003); Lancaster (2004).
This method treats the endogenous variable D and the cost-effectiveness outcomes as covariant and
estimates the effect of treatment allocation, as follows. Let (Di, Y1i, Y2i)> be the transpose of vector
of outcomes, which now includes treatment received, as well as the bivariate endpoints of interest. We
treat all three variables as multivariate normally distributed, so thatDiY1i
Y2i
 ∼ N

 µ0iµ1i
µ2i
 ,Σ =
σ20 s01 s02s01 σ21 s12
s02 s12 σ
2
2

 ;
µ0i = β0,0 + β1,0Zi
µ1i = β0,1 + β1,1β1,0Zi
µ2i = β0,2 + β1,2β1,0Zi
(10)
7
where sij = cov(Yi, Yj), and the causal treatment effect estimates are β1,1 and β1,2 respectively. For
the implementation, we use vague normal priors for the regression coefficients, i.e. βm,j ∼ N(0, 102),
for j ∈ {0, 1, 2},m ∈ {0, 1}, and a Wishart prior for the inverse of Σ (Gelman and Hill, 2006).
4 Simulation study
We now use a factorial simulation study to assess the finite sample performance of the alternative
methods. The first factor is the proportion of participants who do not comply with the experimental
regime, when assigned to it, expressed as a percentage of the total (one-sided non-compliance). Bias is
expected to increase with increasing levels of non-compliance. A systematic review (Dodd et al., 2012)
found that the percentage of non-compliance was less than 30% in two-thirds of published RCTs, but
greater than 50% in one-tenth of studies. Here, two levels of non-compliance are chosen, 30% and 70%.
As costs are typically skewed, three different distributions (Normal, Gamma or Inverse Gaussian – IG)
are used to simulate cost data. As the 2sls approach fails to accommodate the correlation between the
endpoints, we examined the impact of different levels of correlation on the methods’ performance; ρ
takes one of four values ±0.4, ±0.8. The final factor is the sample size of the RCT, taking two settings
n = 100, and 1000. In total, there are 2× 3× 4× 2 = 48 simulated scenarios.
To generate the data, we begin by simulating U ∼ N(0.50, 0.252), independently from treatment
allocation. U represents a pre-randomisation variable that is a common cause of both the outcomes
and the probability of non-compliance, i.e. it is a confounding variable, which we assume is unobserved.
Now, let Si ∼ Bern(pis) be the random variable denoting whether the ith individual switches from
allocated active treatment to control. The probability pis of one-way non-compliance with allocated
treatment depends on U , in the following way,
pis =
p+ 0.1, if u > 0.5,p− 0.1, otherwise (11)
where p denotes the corresponding average non-compliance percentage expressed as a probability, i.e
here p ∈ {0.3, 0.7}. We now generate Di, the random variable of treatment received as
Di =
Zi, if either si = 0 or Zi = 0,1− Zi, if si = 1 and Zi = 1 (12)
where Zi denotes the random allocation for subject i.
Then, the means for both outcomes are assumed to depend linearly on treatment received and the
unobserved confounder U as follows:
µ1 = E[Y1] = 1.2 + 0.4Di + 0.16(ui − 0.5) (13)
µ2 = E[Y2] = 0.5 + 0.2Di + 0.04(ui − 0.5) (14)
Finally, the bivariate outcomes are generated using Gaussian copulas, initially with normal marginals.
In subsequent scenarios, we consider Gamma or Inverse Gaussian marginals for Y1 and normal for Y2.
The conditional correlation between the outcomes, ρ, is set according to the corresponding scenario.
For the scenarios where the endpoints are assumed to follow a bivariate normal distribution, the
variances of the outcomes are set to σ21 = 0.22, σ22 = 0.12 respectively, while for scenarios with Gamma
and IG distributed Y1, the shape parameter is η = 4. For the Gamma case, this gives a variance for
Y1 equal to σ21 = 0.36 in control and σ21 = 0.64 in the intervention group. When Y1 ∼ IG(µ1, η), the
expected variance in the control group is σ21 = 0.432, and σ21 = 1.024 in those receiving the intervention.
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The simulated endpoints represent cost-effectiveness variables that have been rescaled for compu-
tational purposes, with costs divided by 1000, and QALYs by 0.1, such that the true values are £400
(incremental costs), and 0.02 (incremental QALYs) and so with a threshold value of λ = £30000 per
QALY, the true causal INB is £200.
For each simulated scenario, we obtained M = 2500 sets. For the Bayesian analyses, we use the
median of the posterior distribution as the ‘estimate’ of the parameter of interest, and the standard
deviation of the posterior distribution as the standard error. Equi-tailed 95% posterior credible intervals
are also obtained. We use the term confidence interval for the Bayesian credible intervals henceforth,
to have a unified terminology for both Bayesian and frequentist intervals.
Once the corresponding causal estimate has been obtained in each of the 2500 replicated sets under
each scenario in turn, we compute the median bias of the estimates, coverage of 95% confidence intervals
(CI), median CI width and root mean square error (RMSE). We report median bias as opposed to mean
bias, because the BFL leads to a posterior distribution of the causal parameters which is Cauchy-like
(Kleibergen and Zivot, 2003). A method is ‘adequate’, if it results in low levels of bias (median bias
≤ 5%) with coverage rates within 2.5% of the nominal value.
Implementation:
The 3sls was fitted using systemfit package in R using FGLS, and the Bayesian methods were run
using JAGS from R (r2jags). Two chains, each one with 5000 initial iterations and 1000 burn-in
were used. The multiple chains allowed for a check of convergence by the degree of their mixing and
the initial iterations enabled to estimate iteration autocorrelation. A variable number of further 1000-
iteration runs were performed until convergence was reached as estimated by the absolute value of the
Geweke statistics for the first 10% and last 50% of iterations in a run being below 2.5. A final additional
run of 5000 iterations was performed for each chain to achieve a total sample of 10000 iterations, and
a MC error of about 1% of the parameter SE on which to base the posterior estimates. For the uBGN,
an offset of 0.01 is added to the shape parameter ν1 for the Gamma distribution of the cost, to prevent
the sampled shape parameter to become too close to zero, which may result in infinite densities. See
the Appendix for the JAGS model code for BFL.
4.1 Simulation Study Results
Bias
Figure 1 shows the median bias corresponding to scenarios with 30% non-compliance, by cost distri-
butions (left to right) and levels of correlation between the two outcomes, for sample sizes of n = 100
(upper panel) and n = 1000 (lower panel). With the larger sample size, for all methods, bias is neg-
ligible with normally distributed costs, and remain less than 5% when costs are Gamma-distributed.
However, when costs follow an Inverse Gaussian distribution, and the absolute levels of correlation
between the endpoints are high (±0.8), the uBGN approach results in biased estimates, around 10%
bias for the estimated incremental cost, and between 20 and 40% for the estimated INB. With the
small sample size and when costs follow a Gamma or Inverse Gaussian distribution, both unadjusted
Bayesian methods provide estimates with moderate levels of bias. With 70% non-compliance (Fig-
ure A3 in the Appendix), the unadjusted methods result in important biases which persist even with
large sample sizes, especially for scenarios with non-normal outcomes. For small sample settings, uBN
reports positive bias (10 to 20%) in the estimation of incremental QALYs, and the resulting INB,
irrespective of the cost distribution. The uBGN method reports relatively unbiased estimates of the
QALYs, but large positive bias (up to 60%) in the estimation of costs, and hence, there is substan-
tial bias in the estimated INB (up to 200%). Unadjusted Bayesian methods estimates are biased in
the direction of the true causal effect, because these methods ignore the positive correlation between
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treatment received and each outcome introduced by the confounding variable. By contrast, the BFL
and the 3sls provide estimates with low levels of bias across most settings.
CI coverage and width
Table 2 presents the results for CI coverage and width, for scenarios with a sample size of n = 100,
absolute levels of correlation between the endpoints of 0.4, and 30% non-compliance. All other results
are shown in the Appendix. The 2sls INB ignores the correlation between costs and QALYs, and thus,
depending on the direction of this correlation, 2sls reports CI coverage that is above (positive corre-
lation) or below (negative correlation) nominal levels. This divergence from nominal levels increases
with higher absolute levels of correlation (see Appendix, Table A6).
The uBN approach results in over-coverage across many settings, with wide CIs. For example,
for both levels of non-compliance and either sample size, when the costs are Normal, the CI coverage
rates for both incremental costs and QALYs exceed 0.98. The interpretation offered by Burgess and
Thompson (2012) is also relevant here: the uBN assumes that the treatment received and the outcomes
variance structures are uncorrelated, and so when the true correlation is positive, the model overstates
the variance and leads to wide CIs. By contrast, the uBGN method results in low CI coverage rates
for the estimation of incremental costs, when costs follow an inverse Gaussian distribution. This is
because the model incorrectly assumes a Gamma distribution, thereby underestimating the variance.
The extent of the under-coverage appears to increase with higher absolute values of the correlation
between the endpoints, with coverage as low as 0.68 (incremental costs) and 0.72 (INB) in scenarios
where the absolute value of correlation between costs and QALYs is 0.8. (see Appendix, Table A7).
The BFL approach reports estimates with CI coverage close to the nominal when the sample size
is large, but with excess coverage (greater than 0.975), and relatively wide CI, when the sample size is
n = 100 (see Table 2 for 30% noncompliance, and Table A4 in the Appendix for the result correspond-
ing to 70% non-compliance). By contrast, the 3sls reports CI coverage within 2.5% of nominal levels
for each sample size, level of non-compliance, cost distribution and level of correlation between costs
and QALYs.
RMSE
Table 2 reports RMSE corresponding to 30% non-compliance, and n = 100. The least squares ap-
proaches result in lower RMSE than the other methods for the summary statistic of interest, the INB.
This pattern is repeated across other settings, see the Appendix, Tables A10–A16.
5 Results for the motivating example
We now compare the methods in practice by applying them to the REFLUX dataset. Only 48% of
the individuals have completely observed cost-effectiveness outcomes: there were 185 individuals with
missing QALYs, 166 with missing costs, and a further 13 with missing EQ5D0 at baseline, with about
a third of those with missing outcomes having switched from their allocated treatment. These missing
data not only bring more uncertainty to our analysis, but more importantly, unless the missing data
are handled appropriately can lead to biased causal estimates (Daniel et al., 2012). A complete case
analysis would be unbiased, albeit inefficient, if the missingness is conditionally independent of the
outcomes given the covariates in the model (White et al., 2010), even when the covariates have missing
data, as is the case here.4 Alternatively, a more plausible assumption is to assume the missing data
are missing at random (MAR), i.e. the probability of missingness depends only on the observed data,
and use multiple imputation (MI) or a full Bayesian analysis to obtain valid inferences.
Therefore, we perform MI prior to carrying out 2sls and 3sls analyses. We begin by investigating
4This mechanism is a special case of missing not at random.
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all the possible associations between the covariates available in the data set and the missingness,
univariately for costs, QALYs and baseline EQ5D0. Covariates which are predictive of both, the
missing values and the probability of missing, are to be included in the imputation model as auxiliary
variables, as conditioning on more variables helps make the MAR assumption more plausible. None
of the fully observed variables at our disposal (age, sex, and baseline BMI) satisfies these criteria
and therefore, we do not include any auxiliary variables in our imputation models. Thus, we impute
total cost, total QALYs and baseline EQ5D0, 50 times by chained equations, using predictive mean
matching (PMM), taking the 5 nearest neighbours as donors (White et al., 2011), including treatment
received in the imputation model and stratifying by treatment allocation. We perform 2sls on costs
and QALYs independently and calculate (within MI) SE for the INB assuming independence between
costs and QALYs. For the 3sls approach, the model is fitted to both outcomes simultaneously, and
the post-estimation facilities are used to extract the variance-covariance estimate, and compute the
estimated INB and its corresponding SE. We also use the CACE estimates of incremental cost and
QALYs to obtain the ICER. After applying each method to the 50 MI sets, we combine the results
using Rubin’s rules (Rubin, 1987).5
For the Bayesian approaches, the missing values become extra parameters to model. Since baseline
EQ5D0 has missing observations, a model for its distribution is added EQ5D0 ∼ N(µq0, σ2q0), with a
vaguely informative prior for µq0 ∼ Unif(−0.5, 1), and an uninformative prior for |σq0| ∼ N(0, 0.01).
We add two extra lines of code to the models to obtain posterior distributions for INB and ICERs.
We center the outcomes around the empirical mean (except for costs, when modelled as Gamma) and
re-scale the costs (dividing by 1000) to improve mixing and convergence. We use two chains, initially
running 15,000 iterations with 5,000 as burn-in. After checking visually for auto-correlation, an extra
10,000 iterations are needed to ensure that the density plots of the parameters corresponding to the
two chains are very similar, denoting convergence to the stationary distribution. Enough iterations for
each chain are kept to make the total effective sample (after accounting for auto-correlation) equal to
10,000. 6
Table 1 shows the results for incremental costs, QALYs and INB for the motivating example adjusted
for baseline EQ5D0. Bayesian posterior distribution are summarised by their median value and 95%
credible intervals. The CACEs are similar across the methods, except for uBGN, where the incremental
QALYs CACE is nearly halved, resulting in a smaller INB with a CI that includes 0. In line with the
simulation results, this would suggest that, where the uBGN is misspecified according to the assumed
cost distribution, it can provide a biased estimate of the incremental QALYs.
Comparing the CACEs to the ITT, we see that the incremental cost estimates increases between
an ITT and a CACE, as actual receipt of surgery carries with it higher costs that the mere offering
of surgery does not. Similarly, the incremental QALYs are larger, meaning that amongst compli-
ers, those receiving surgery have a greater gain in quality of life, over the follow-up period. The
CACE for costs are relatively close to the per-protocol incremental costs reported in the original study,
£2324 (1780, 2848). In contrast, the incremental QALYs according to PP on complete-cases originally
reported was 0.3200 (0.0837, 0.5562), considerably smaller than our CACE estimates (Grant et al.,
2013). The ITT ICER obtained after MI was £4135, while using causal incremental costs and QALYs,
the corresponding estimates of the CACE for ICER were £4140 (3sls), £5189 (uBN), £5960 (uBGN),
5Applying IV 2sls and 3sls with multiply imputed datasets, and combining the results using Rubin’s rules can be
done automatically in Stata using mi estimate, cmdok: ivregress 2sls and mi estimate, cmdok: reg3. In R,
ivregress can be used with with.mids command within mice, but systemfit cannot presently be combined with this
command so, Rubin’s rules have to be coded manually. Sample code is available in the Appendix.
6Multivariate normal nodes cannot be partially observed in JAGS, thus, we run BFL models on all available data
within WinBUGs. An observation with zero costs was set to missing when running the Bayesian Gamma model, which
requires strictly positive costs.
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and £3948 (BFL). The originally reported per-protocol ICER is £7932 per extra QALY was obtained
on complete cases only (Grant et al., 2013).
These results may be sensitive to the modelling of the missing data. As a sensitivity analysis to the
MAR assumption, we present the complete case analysis in Table A1 in the Appendix. The conclusions
from complete-case analysis are similar to those obtained under MAR.
We also explore the sensitivity to choices of priors, by re-running the BFL analyses using different
priors, first for the multivariate precision matrix, keeping the priors for the coefficients normal, and
then a second analysis, with uniform priors for the regression coefficient, and an inverse Wishart prior
with 6 degrees of freedom and a identity scale matrix, for the precision. The results are not materially
changed (see Appendix, Table A2).
The results of the within-trial CEA suggest that amongst compliers, laparoscopy is more cost-
effective than medical management for patients suffering from GORD. The results are robust to the
choice of priors, and to the assumptions about the missing data mechanism. The results for the
uBGN differ somewhat from the other models, and as our simulations show, the concern is that such
unadjusted Bayesian models are prone to bias from model misspecification.
6 Discussion
This paper extends existing methods for CEA (Willan et al., 2003; Nixon and Thompson, 2005), by pro-
viding IV approaches for obtaining causal cost-effectiveness estimates for RCTs with non-compliance.
The methods developed here however are applicable to other settings with multivariate continuous
outcomes more generally, for example RCTs in education, with different measures of attainment being
combined into an overall score. To help dissemination, we provide code in the Appendix.
We proposed exploiting existing 3sls methods and also considered IV Bayesian models, which
are extensions of previously proposed approaches for univariate continuous outcomes. Burgess and
Thompson (2012) found the BFL was median unbiased and gave CI coverage close to nominal levels,
albeit with wider CIs than least-squares methods. Their ‘unadjusted Bayesian’ method, similar to
our uBN approach, assumes that the error term for the model of treatment received on treatment
allocated is uncorrelated with the error from the outcome models. This results in bias in the direction
of the true association, and affects the CI coverage. Our simulation study shows that, in a setting with
multivariate outcomes, the bias can be substantial. A potential solution to this could be using priors for
the error terms that reflect this dependency explicitly. For example, Rossi et al. (2012) propose using a
prior for the errors that explicitly depends on the coefficient β1,0, the effect of treatment allocation on
treatment received, in equation (8). Kleibergen and Zivot (2003) propose priors that also reflect this
dependency explicitly, and replicate better the properties of the 2sls. This is known as the “Bayesian
two-stage approach”.
The results of our simulations show that applying 2sls separately to the univariate outcomes leads
to inaccurate 95% CI around the INB, even with moderate levels of correlation between costs and
outcomes (±0.4). Across all the settings considered, the 3sls approach resulted in low levels of bias for
the INB and unlike 2sls, provided CI coverage close to nominal levels. BFL performed well with large
sample sizes, but produced standard deviations which were too large when the sample size was small,
as can be seen from the over-coverage, with wide CIs.
The REFLUX study illustrated a common concern in CEA, in that the levels of non-compliance
in the RCT were different, in this case higher, to those in routine practice. The CACEs presented
provide the policy-maker with an estimate of what the relative cost-effectiveness would be if all the
RCT participants had complied with their assigned treatment, which is complementary to the ITT
estimate. Since we judged the IV assumptions for identification likely to hold in this case-study, we
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conclude that either 3sls or BFL provide valid inferences for the CACE of INB. The re-analysis of the
REFLUX case study also provided the opportunity to investigate the sensitivity to the choice of priors
in practice. Here we found that our choice of weakly informative priors, which were relatively flat in
the region where the values of the parameters were anticipated to be, together with samples of at least
size 100, had minimal influence on the posterior estimates. We repeated the analysis using different
vague priors for the parameters of interests and the corresponding results were not materially changed.
We considered here relatively simple frequentist IV methods, namely 2sls and 3sls. One alternative
approach to the estimation of CACEs for multivariate responses, is to use linear structural equation
modelling, estimated by maximum-likelihood expectation-maximization (ML-EM) algorithm (Jo and
Muthén, 2001). Further, we only considered those settings where a linear additive treatment effect is of
interest, and the assumptions for identification are met. Where interest lies in systems of simultaneous
non-linear equations with endogeneous regressors, GMM or generalised structural equation models can
be used to estimate CACEs (Davidson and MacKinnon, 2004).
There are several options to study the sensitivity to departures from the identification assumptions.
For example, if the exclusion restriction does not hold, a Bayesian parametric model can use priors
on the non-zero direct effect of randomisation on the outcome for identification (Conley et al., 2012;
Hirano et al., 2000). Since the models are only weakly identified, the results would depend strongly on
the parametric choices for the likelihood and the prior distributions. In the frequentist IV framework,
such modelling is also possible, see Baiocchi et al. (2014) for an excellent tutorial on how to conduct
sensitivity analysis to violations of the ER and monotonicity assumptions. Alternatively, violations
of the ER can also be handled by using baseline covariates to model the probability of compliance
directly, within structural equation modelling via ML-EM framework (Jo, 2002a,b).
Settings where the instrument is only weakly correlated with the endogenous variable have not been
considered here, because for binary non-compliance with binary allocation, the percentage of one-way
non-compliance would need to be in excess of 85%, for the F-statistic of the randomization instrument
to be less than 10, the traditional cutoff beneath which an instrument is regarded as ‘weak’. Such
levels of non-compliance are not realistic in practice, with the reported median non-compliance equal
to 12% (Zhang et al., 2014). Nevertheless, Bayesian IV methods have been shown to perform better
than 2sls methods when the instrument is weak (Burgess and Thompson, 2012).
Also, for simplicity, we restricted our analysis of the case study to MAR and complete cases
assumptions. Sensitivity to departures from these assumptions is beyond the scope of this paper, but
researchers should be aware of the need to think carefully about the possible causes of missingness,
and conduct sensitivity analysis under MNAR, assuming plausible differences in the distributions of
the observed and the missing data. When addressing the missing data through Bayesian methods,
the posterior distribution can be sensitive to the choice of prior distribution, especially with a large
amount of missing data (Hirano et al., 2000).
Future research directions could include exploiting the additional flexibility of the Bayesian frame-
work to incorporate informative priors, perhaps as part of a comprehensive decision modelling approach.
The methods developed here could also be extended to handle time-varying non-compliance.
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Figure 1: Median Bias for scenarios with 30% non-compliance and sample sizes of (a) n = 100 (top) and (b) n = 1000.
Results are stratified by cost distribution, and correlation between cost and QALYs. The dotted line represents zero
bias. Results for 2sls (not plotted) are identical to those for 3sls; uBGN was not applied to Normal cost data.
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Table 1: The REFLUX study: descriptive statistics and cost-effectiveness according to ITT and alternative methods
for estimating the CACE. Follow-up period is five years, and treatment switches are defined within the first year post
randomisation. Costs and INB numbers rounded to the nearest integer.
Medical management Laparoscopic surgery
N Assigned 179 178
N (%) Switched 10 (8.3) 67 (28.4)
N (%) missing costs 83 (46) 83 (47)
Mean (SD) observed cost in £ 1258 (1687) 2971 (1828)
N (%) missing QALYs 91 (51) 94 (53)
Mean (SD) observed QALYs 3.52 (0.99) 3.74 (0.90)
Baseline variables
N (%) missing EQ5D0 6 (3) 7 (4)
Mean (SD) observed EQ5D0 0.72 (0.25) 0.71 (0.26)
Correlation between costs and QALYs −0.42 −0.07
Correlation of costs and QALYs −0.36 −0.18
by treatment received
Incremental costs, QALYs and INB of surgery vs medicine
Outcome Method estimate ( 95% CI )
Incremental cost
ITT 1103 (593, 1613)
2sls 1899 (1073, 2724)
3sls 1899 (1073, 2724)
uBN 2960 (2026, 3998)
uBGN 2176 (1356, 3031)
BFL 2030 (1170, 2878)
Incremental QALYs
ITT 0.295 (0.002, 0.589)
2sls 0.516 (0.103, 0.929)
3sls 0.516 (0.103, 0.929)
uBN 0.568 (0.181, 0.971)
uBGN 0.268 (−0.229, 0.759)
BFL 0.511 (0.121, 0.947)
INB
ITT 7763 (−1059, 16585)
2sls 13587 (1101, 26073)
3sls 13587 (1002, 26173)
uBN 14091 (2485, 26086)
uBGN 5869 (−9204, 20740)
BFL 13340 (1406, 26315)
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Table 2: CI Coverage rates (CR) and median width for incremental cost, QALYs, and INB, across scenarios with
30% non-compliance, sample size n = 100 and moderate correlation between outcomes (with odd rows corresponding to
positive correlation ρ and even rows to negative). uBGN was not applied in settings with normal cost data.
2sls 3sls uBN uBGN BFL
Y1 ∼ N CR CIW CR CIW CR CIW CR CIW CR CIW
Cost .952 .228 .952 .228 .992 .312 .988 .299
ρ < 0 .952 .229 .952 .229 .993 .325 .986 .297
QALYs .946 .112 .946 .112 .988 .155 .950 .121
ρ < 0 .950 .113 .950 .113 .992 .163 .950 .121
INB .988 405 .953 319 .982 398 .966 376
ρ < 0 .900 409 .948 475 .951 509 .962 525
Y1 ∼ G
Cost .952 .756 .952 .756 .955 .815 .941 .818 .954 .823
ρ < 0 .942 .759 .942 .759 .949 .828 .936 .822 .945 .811
QALYs .959 .113 .959 .113 .993 .160 .960 .122 .960 .122
ρ < 0 .959 .113 .949 .113 .995 .163 .954 .122 .954 .122
INB .982 829 .948 696 .958 764 .942 748 .956 760
ρ < 0 .914 833 .948 943 .930 921 .941 1019 .951 1014
Y1 ∼ IG
Cost .951 .880 .951 .880 .958 .949 .904 .866 .956 .945
ρ < 0 .950 .878 .950 .878 .958 .951 .905 .864 .954 .932
QALYs .945 .112 .945 .112 .991 .161 .944 .120 .999 .206
ρ < 0 .954 .112 .954 .112 .993 .161 .952 .120 .999 .204
INB .980 944 .954 818 .959 889 .917 814 .984 1001
ρ < 0 .917 942 .947 1049 .934 1034 .911 1041 .971 1203
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Table 3: RMSE for incremental Cost, QALYs and INB across scenarios with 30% non-compliance, moderate
correlation between outcomes and sample size n = 100. uBGN was not applied in settings with normal cost
data. Numbers for INB have been rounded to the nearest integer.
Cost distribution ρ 3sls (2sls) uBN uBGN BFL
Normal Cost
0.4 0.058 0.060 0.059
-0.4 0.060 0.062 0.061
QALYs
0.4 0.029 0.030 0.030
-0.4 0.029 0.030 0.030
INB
0.4 83 84 87
-0.4 125 127 125
Gamma Cost
0.4 0.198 0.202 0.212 0.202
-0.4 0.200 0.204 0.212 0.203
QALYs
0.4 0.030 0.030 0.030 0.029
-0.4 0.029 0.030 0.030 0.030
INB
0.4 181 184 193 184
-0.4 246 251 261 252
Inverse Cost
Gaussian 0.4 0.230 0.232 0.252 0.232
-0.4 0.230 0.232 0.250 0.232
QALYs
0.4 0.029 0.030 0.030 0.030
-0.4 0.029 0.030 0.030 0.030
INB
0.4 211 214 231 214
-0.4 273 278 296 278
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A Sensitivity analyses for the REFLUX RCT
Our motivating example trial had over 50% missing cost-effectiveness outcomes, with a few missing
data in the baseline covariate. As primary analysis, we performed MI and full Bayesian analyses, that
intrinsically obtain a predictive posterior distribution for these missing values, and reported the results
of these analyses in the main text.
As a sensitivity to the MAR assumption, we present here the complete case analysis (N=172) of the
REFLUX RCT, adjusting for baseline EQ5D. The results are valid if conditional on baseline EQ5D,
the missing data mechanism is independent of the outcomes.
Table A1: Estimated cost-effectiveness for the REFLUX RCT, over a time horizon of five years according to
ITT and alternative methods for estimating the CACE based on complete cases. Treatment switches are defined
within the first year post randomisation. Costs and INB numbers rounded to the nearest integer.
Incremental costs, QALYs and INB of surgery vs medicine
Outcome Method estimate ( 95% CI )
Incremental cost
ITT 1626 (1098, 2153)
2sls 2102 (1484, 2720)
3sls 2102 (1484, 2720)
uBN 2112 (1401, 2879)
uBGN 2195 (1481, 3065)
BFL 2081 (1457, 2705)
Incremental QALYs
ITT 0.319 (−0.055, 0.694)
2sls 0.412 (0.137, 0.688)
3sls 0.412 (0.137, 0.688)
uBN 0.413 (0.136, 0.704)
uBGN 0.285 (−0.066, 0.629)
BFL 0.414 (0.135, 0.703)
INB
ITT 7948. (−3259, 19155)
2sls 10275 (1997, 18554)
3sls 10275 (1828, 18724)
uBN 10280, (1947, 18980)
uBGN 6362 − 4497, 16941)
BFL 10353 (1789, 19165)
As can be seen in Table A1, the conclusions each model reaches are not substantially changed from
those under MAR (either using MI or full Bayesian), presented in the main text.
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A.1 Sensitivity analysis of the BFL to choice of priors
We now study the sensitivity of the BFL model to the choice of priors for the parameters in the model.
Recall that this model can be written as DiY1i
Y2i
 ∼ N

 µ0iµ1i
µ2i
 ,Σ
 Σ =
 σ20 s01 s02s01 σ21 s12
s02 s12 σ
2
2
 (15)
where sij = cov(Yi, Yj), and
µ0i = β0,0 + β1,0Zi
µ1i = β0,1 + β1,1β1,0Zi
µ2i = β0,2 + β1,2β1,0Zi (16)
Originally, we chose normal priors for the regression coefficients, βm,j ∼ N(0, 102), for j ∈ {0, 1, 2},m ∈
{0, 1}, and a Wishart prior for the inverse of Σ (Gelman and Hill, 2006).
Here, we first vary the prior distribution for Σ, and assume a structured covariance matrix (see
Congdon (2007) example 5.8, and Lunn et al. (2012), example 9.1.4). Thus, we write:
Σ =
 s00s00 ρ1s00s11 ρ2s00s22ρ1s00s11 s11s11 ρ3s11s22
ρ2s00s22 ρ3s11s22 s22s22
 (17)
and assumed the following priors
sij ∼ N(0, 102), ρj ∼ Unif[−1, 1] (18)
In a secondary sensitivity analysis, we assume a Wishart prior for Σ as before, but used uniform priors
for the regression coefficients, βm,j ∼ Unif[−10, 10], for j ∈ {0, 1, 2},m ∈ {0, 1}. We did these changes
on both available cases and complete cases. The results corresponding to INB are reported in Table
A2.
Table A2: Results from sensitivity analysis of the BFL to prior specifications for the INB of the
motivating example: CEA within the REFLUX trial. INB reported to the nearest integer, in Great
British Pounds (GBP).
Data Priors INB estimate 95% CI
Available cases Structured precision matrix1 10421 (1878, 19187)
normal priors for βm,j
Available cases Wishart prior for the precision 10405 (1733, 19330)
Unif prior for βm,j
Complete cases Structured precision matrix 10425 (1792, 19156)
normal priors for βm,j
Complete cases Wishart prior for the precision 10428 (1894, 19279)
Unif prior for βm,j
1 Following the specifications of equation (18) in this Appendix.
B Supplementary Results from the simulations
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Figure 2: Median Bias for scenarios with 70% non-compliance and sample sizes of (a) n = 100 (top) and (b) n = 1000.
Results are stratified by cost distribution, and correlation between cost and QALYs. The dotted line represents zero
bias. Results for 2sls (not plotted) are identical to those for 3sls; uBGN was not applied to Normal cost data.
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Table A10: RMSE for incremental Cost, QALYs and INB across scenarios with 30% non-compliance,
high correlation between outcomes and sample size n = 100. uBGN was not applied in settings with
normal cost data. Numbers for INB have been rounded to the nearest integer.
Cost distribution ρ 3sls (2sls) uBN uBGN BFL
Normal Cost
0.8 0.059 0.060 0.060
-0.8 0.059 0.061 0.060
QALYs
0.8 0.029 0.030 0.030
-0.8 0.029 0.030 0.030
INB
0.8 54 55 56
-0.8 137 140 139
Gamma Cost
0.8 0.192 0.196 0.194 0.196
-0.8 0.196 0.200 0.205 0.200
QALYs
0.8 0.029 0.030 0.030 0.030
-0.8 0.029 0.030 0.030 0.030
INB
0.8 138 141 137 141
-0.8 271 276 281 276
Inverse Cost
Gaussian 0.8 0.226 0.229 0.272 0.229
-0.8 0.225 0.228 0.272 0.228
QALYs
0.8 0.029 0.030 0.032 0.030
-0.8 0.028 0.029 0.031 0.029
INB
0.8 175 178 210 178
-0.8 291 296 345 296
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Table A11: RMSE for incremental Cost, QALYs and INB across scenarios with 30% non-compliance,
moderate correlation between outcomes and sample size n = 1000. uBGN was not applied in settings
with normal cost data. Numbers for INB have been rounded to the nearest integer.
Cost distribution ρ 3sls (2sls) uBN uBGN BFL
Normal Cost
0.4 0.018 0.018 0.018
-0.4 0.018 0.018 0.018
QALYs
0.4 0.009 0.009 0.009
-0.4 0.009 0.009 0.009
INB
0.4 26 26 26
-0.4 38 38 39
Gamma Cost
0.4 0.061 0.061 0.061 0.061
-0.4 0.061 0.061 0.061 0.061
QALYs
0.4 0.009 0.009 0.009 0.009
-0.4 0.009 0.009 0.009 0.009
INB
0.4 55 55 56 55
-0.4 75 75 76 75
Inverse Cost
Gaussian 0.4 0.072 0.072 0.075 0.072
-0.4 0.072 0.072 0.076 0.073
QALYs
0.4 0.009 0.009 0.035 0.009
-0.4 0.009 0.009 0.035 0.009
INB
0.4 66 66 69 66
-0.4 85 86 89 86
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Table A12: RMSE for incremental Cost, QALYs and INB across scenarios with 30% non-compliance,
high correlation between outcomes and sample size n = 1000. uBGN was not applied in settings with
normal cost data. Numbers for INB have been rounded to the nearest integer.
Cost distribution ρ 3sls (2sls) uBN uBGN BFL
Normal Cost
0.8 0.019 0.019 0.019
-0.8 0.018 0.018 0.018
QALYs
0.8 0.009 0.009 0.009
-0.8 0.009 0.009 0.009
INB
0.8 17 17 17
-0.8 43 43 44
Gamma Cost
0.8 0.062 0.062 0.061 0.062
-0.8 0.062 0.062 0.062 0.062
QALYs
0.8 0.009 0.009 0.009 0.009
-0.8 0.009 0.009 0.009 0.009
INB
0.8 44 44 43 44
-0.8 85 85 84 85
Inverse Cost
Gaussian 0.8 0.073 0.073 0.105 0.073
-0.8 0.072 0.072 0.103 0.072
QALYs
0.8 0.009 0.009 0.011 0.009
-0.8 0.009 0.009 0.011 0.009
INB
0.8 56 56 80 56
-0.8 94 94 132 94
30
Table A13: RMSE for incremental Cost, QALYs and INB across scenarios with 70% non-compliance,
moderate correlation between outcomes and sample size n = 100. uBGN was not applied in settings
with normal cost data. Numbers for INB have been rounded to the nearest integer.
Cost distribution ρ 3sls (2sls) uBN uBGN BFL
Normal Cost
0.4 0.145 0.207 0.181
-0.4 0.146 0.203 0.182
QALYs
0.4 0.074 0.104 0.089
-0.4 0.074 0.109 0.088
INB
0.4 212 272 264
-0.4 309 396 383
Gamma Cost
0.4 0.467 0.565 0.682 0.559
-0.4 0.456 0.553 0.636 0.549
QALYs
0.4 0.072 0.097 0.082 0.085
-0.4 0.073 0.099 0.083 0.086
INB
0.4 426 520 429 500
-0.4 570 697 758 687
Inverse Cost
Gaussian 0.4 0.521 0.622 0.946 0.622
-0.4 0.516 0.635 1.096 0.635
QALYs
0.4 0.073 0.094 0.092 0.094
-0.4 0.074 0.092 0.110 0.092
INB
0.4 484 583 632 583
-0.4 630 865 967 865
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Table A14: RMSE for incremental Cost, QALYs and INB across scenarios with 70% non-compliance,
high correlation between outcomes and sample size n = 100. uBGN was not applied in settings with
normal cost data. Numbers for INB have been rounded to the nearest integer.
Cost distribution ρ 3sls (2sls) uBN uBGN BFL
Normal Cost
0.8 0.147 0.201 0.180
-0.8 0.147 0.209 0.182
QALYs
0.8 0.072 0.100 0.086
-0.8 0.075 0.109 0.090
INB
0.8 131 169 169
-0.8 351 447 425
Gamma Cost
0.8 0.450 0.543 0.604 0.531
-0.8 0.454 0.546 0.563 0.538
QALYs
0.8 0.072 0.097 0.081 0.086
-0.8 0.073 0.096 0.084 0.086
INB
0.8 313 377 429 368
-0.8 638 768 758 773
Inverse Cost
Gaussian 0.8 0.532 0.637 0.902 0.637
-0.8 0.526 0.635 1.010 0.635
QALYs
0.8 0.074 0.092 0.100 0.092
-0.8 0.074 0.092 0.096 0.092
INB
0.8 395 468 615 468
-0.8 704 865 1022 865
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Table A15: RMSE for incremental Cost, QALYs and INB across scenarios with 70% non-compliance,
moderate correlation between outcomes and sample size n = 1000. uBGN was not applied in settings
with normal cost data. Numbers for INB have been rounded to the nearest integer.
Cost distribution ρ 3sls (2sls) uBN uBGN BFL
Normal Cost
0.4 0.043 0.043 0.043
-0.4 0.043 0.043 0.043
QALYs
0.4 0.022 0.022 0.022
-0.4 0.022 0.022 0.022
INB
0.4 61 62 62
-0.4 90 91 91
Gamma Cost
0.4 0.135 0.135 0.138 0.136
-0.4 0.134 0.135 0.138 0.135
QALYs
0.4 0.021 0.021 0.021 0.021
-0.4 0.021 0.021 0.021 0.021
INB
0.4 124 169 126 125
-0.4 168 169 172 170
Inverse Cost
Gaussian 0.4 0.151 0.153 0.158 0.153
-0.4 0.152 0.153 0.158 0.153
QALYs
0.4 0.021 0.022 0.022 0.022
-0.4 0.021 0.022 0.022 0.022
INB
0.4 141 142 147 142
-0.4 185 187 193 187
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Table A16: RMSE for incremental Cost, QALYs and INB across scenarios with 70% non-compliance,
high correlation between outcomes and sample size n = 1000. uBGN was not applied in settings with
normal cost data. Numbers for INB have been rounded to the nearest integer.
Cost distribution ρ 3sls (2sls) uBN uBGN BFL
Normal Cost
0.8 0.043 0.043
-0.8 0.043 0.043 0.043
QALYs
0.8 0.021 0.021 0.021
-0.8 0.021 0.022 0.021
INB
0.8 39 39 39
-0.8 100 101 101
Gamma Cost
0.8 0.135 0.137 0.135 0.137
-0.8 0.133 0.135 0.133 0.135
QALYs
0.8 0.021 0.022 0.022 0.021
-0.8 0.021 0.021 0.021 0.021
INB
0.8 95 96 94 96
-0.8 187 188 186 188
Inverse Cost
Gaussian 0.8 0.155 0.157 0.190 0.157
-0.8 0.151 0.153 0.192 0.153
QALYs
0.8 0.021 0.021 0.023 0.021
-0.8 0.021 0.021 0.023 0.021
INB
0.8 118 119 144 119
-0.8 201 203 250 203
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B.1 Software code for performing MI and 3sls in Stata
The code belows performs MI of total costs, total QALYs and the baseline EQ5D summary score
eq5d_b, by chained equations using predictive mean matching with the 5 nearest neighbours (specified
by the option knn(5). We include treatment received txreceived as a variable in the imputation
models, and perform the imputations separately by randomised treatment arm, rnd (done by specifying
the option by (rnd) .
After obtaining 50 imputations, 3sls estimates are obtained, and pooled following Rubin’s rules.
*MI
sort rnd
mi set mlong
mi register imputed total_qalys total_costs eq5d_b
mi impute chained (pmm, knn(5) ) total_qalys eq5d_b total_costs= txreceived,///
by (rnd) add(50) rseed (110)
*3sls
mi estimate, cmdok: reg3 (total_costs total_qalys== txreceived), exog(rnd) ireg
mi estimate(inb: _b[total_qalys:txreceived] *30000 - _b[total_costs:txreceived]), ///
cmdok: reg3 (total_costs total_qalys==txreceived), exog(rnd)
mi estimate (icer: _b[total_costs:txreceived]/_b[total_qalys:txreceived] ), ///
cmdok: reg3 (total_costs total_qalys== txreceived), exog(rnd)
B.2 Software code for performing MI and 3sls in R
The following code performs MI by chain equations using PMM. The default option for the number
of donors is 5, so we do not need to specify this. The code also carries out 3sls using systemfit in
R in each imputed data set. Rubin’s rules for pooling the estimates across imputed sets are coded
manually.
rm(list=ls())
library(MASS,"AER",systemfit,mice,foreign)
data <- read.dta("../data.dta")
#the data must be ordered as follows total_qalys total_costs txreceived eq5d_b
#MI using MICE in R
M<-50 #50 imputations
data<-data[order(data$rnd),] # order data by arm
#we impute separate in each randomised arm
data0<-subset(data,rnd==0)
data1<-subset(data,rnd==1)
#the variable rnd must be dropped from data1 and data0
#rnd=1
imp1 <-mice(data1, m = M, method =c("pmm","pmm", "","pmm"),print=FALSE)
#rnd=0
imp0 <-mice(data0, m = M, method =c("pmm","pmm", "","pmm"),print=FALSE)
##merging data
mj<-imput_no<- rep(1:M, each=length(data$rnd))
data_mi <-data[rep(1:nrow(data), M), ]
data_mi$mj<-imput_no
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data_mi$baseq_imput<-data_mi$qaly_imput<-<-array(NA, dim=M*length(data$rnd))
data_mi$cost_imput<-array(NA, dim=M*length(data$rnd))
for (j in 1:M){
data_mi$baseq_imput[data_mi$mj==j]<-c(complete(imp0,j)$baseq , complete(imp1,j)$baseq)
data_mi$qaly_imput[data_mi$mj==j]<-c(complete(imp0,j)$qaly , complete(imp1,j)$qaly )
data_mi$cost_imput[data_mi$mj==j]<-c(complete(imp0,j)$cost , complete(imp1,j)$cost)
}
######################################################
#### 3sls
######################################################
coef.c<-var.coef.c<-matrix(NA, nrow=M, ncol=1)
coef.q<-var.coef.q<-matrix(NA, nrow=M, ncol=1)
coef.inb<-var.coef.inb<-matrix(NA, nrow=M, ncol=1)
coef.icer.3sls<-matrix(NA, nrow=M, ncol=1)
for (j in 1:M){
eq.cost <- data_mi$cost_imput[data_mi$mj==j] ~
data_mi$exp[data_mi$mj==j]+ data_mi$baseq_imput[data_mi$mj==j]
eq.qaly <- data_mi$qaly_imput[data_mi$mj==j] ~
data_mi$exp[data_mi$mj==j]+ data_mi$baseq_imput[data_mi$mj==j]
eq.Exp.Rand <- data_mi$exp[data_mi$mj==j] ~
data_mi$rnd[data_mi$mj==j]+ data_mi$baseq_imput[data_mi$mj==j]
System3eq <- list( cost=eq.cost, qaly=eq.qaly, trt.received = eq.Exp.Rand )
reg3 <- systemfit(System3eq, method = "3SLS",
inst = ~ data_mi$rnd[data_mi$mj==j] + data_mi$baseq_imput[data_mi$mj==j])
coef.q[j]<-reg3$coefficients["qaly_data_mi$exp[data_mi$mj == j]"]
coef.c[j]<-reg3$coefficients["cost_data_mi$exp[data_mi$mj == j]"]
var.coef.q[j]<-diag(reg3$coefCov)["qaly_data_mi$exp[data_mi$mj == j]"]
var.coef.c[j]<-diag(reg3$coefCov)["cost_data_mi$exp[data_mi$mj == j]"]
cov<-reg3$coefCov["qaly_data_mi$exp[data_mi$mj == j]","cost_data_mi$exp[data_mi$mj == j]"]
coef.inb[j]<- coef.q[j]*30000-coef.c[j]
var.coef.inb[j]<-30000^2*(var.coef.q[j])+ var.coef.c[j] -(2*30000*cov)
coef.icer.3sls[j]<-(coef.c[j])/(coef.q[j])
}
###### Apply Rubin’s rules ####
mean.c <-mean(coef.c)
var.c <-mean(var.coef.c)
with.var.c<- var.c # within-imputation variance
bet.var.c<-(1/(M-1))*sum((coef.c-mean.c)^2)
se.c<- sqrt(with.var.c+(1+1/M)*bet.var.c)
##Q
mean.q <-mean(coef.q)
var.q <-mean(var.coef.q)
with.var.q<- var.q # within-imputation variance
bet.var.q<-(1/(M-1))*sum((coef.q-mean.q)^2)
se.q<- sqrt(with.var.q+(1+1/M)*bet.var.q)
##INB
mean.inb <-mean(coef.inb)
var.inb <-mean(var.coef.inb)
with.var.inb<- var.inb # within-imputation variance
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bet.var.inb<-(1/(M-1))*sum((coef.inb-mean.inb)^2)
se.inb<- sqrt(with.var.inb+(1+1/M)*bet.var.inb)
##ONLY Mean ICER
mean.icer <-mean(coef.icer.3sls)
res.3sls<-c(mean.c, se.c, mean.q, se.q, mean.inb, se.inb, mean.icer)
B.3 Model code for BFL in JAGS
The following model can also be run in WinBUGs. This may be necessary if there is missing outcome
data in the analysis at hand, since multivariate normal nodes cannot be partially observed in the
current version of JAGS.
The vector y=(txreceived, total_qalys,total_costs). The other variables are as before.
model{
for (i in 1:n) {
eq5d_b[i] ~ dnorm(qb, pr.qb)
y[i,1:3] ~ dmnorm(mu[i,], pr[,])
mu[i,1] <- b[1,1] + b[1,2] * rnd[i]
mu[i,2] <- b[2,1] + b[2,2]*b[1,2] * rnd[i] + c*eq5d_b[i]
mu[i,3] <- b[3,1] + b[3,2]* b[1,2] *rnd[i] + g*eq5d_b[i]
}
# Priors:
pr[1:3,1:3]~dwish(R,3)
R<-diag(1,3)
for (k in 1:3) {
b[k,1:2] ~ dmnorm(vm[],vp[,])
}
for (k in 1:2) {
vm[k] <- 0
vp[k,k] <- 0.1
}
vp[1,2] <- 0
vp[2,1] <- 0
pr.qb<- 1 / (qb.sd * qb.sd)
qb.sd <- exp(log.qb.sd)
log.qb.sd ~ dnorm(0, 0.01)
qb ~ dunif(-0.5,1)
c ~ dnorm(0, 0.01)
g ~ dnorm(0, 0.01)
#functionals of the parameters
inb<- 30000*b[2,2]-b[3,2]
icer<- b[3,2]/(b[2,2]+0.000001) #to avoid dividing by a zero
}
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